Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2021Leukemia & lymphoma/Leukemia and lymphoma

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEytan M. SteinGBGaetano BonifacioDLDominick Latrémouille-Viau

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stein et al. (2021) studied this question.

synapsesocial.com/papers/6a190527fd5345ff76be2f32https://doi.org/10.1080/10428194.2020.1869959
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acute Myeloid Leukemia as the Main Cause of Pancytopenia in Iranian Population2017 · 13 citations
  2. 2Bone Marrow Examination in Cases of Pancytopenia2008 · 197 citations
  3. 3The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail2017 · 21 citations
  4. 4Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure2011 · 485 citations
  5. 5The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group2018 · 14 citations